Literature DB >> 1446866

Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation.

M R Lucey1, D M Graham, P Martin, A Di Bisceglie, S Rosenthal, J G Waggoner, R M Merion, D A Campbell, T T Nostrant, H D Appelman.   

Abstract

The clinical course of 10 liver transplant recipients who had hepatitis B virus (HBV) and five recipients with HBV and D (delta) infection before transplantation is described. Six patients who underwent eight transplants died. The estimated one and two year survival rates in patients with HBV only before transplantation were 74% and 67% respectively. The estimated one and two year survival in patients with HBV and HDV infection beforehand was 100%. Graft infection by HBV occurred in 8 of 10 patients infected with HBV only; and in 4 of 5 patients with previous HBV and HDV infection. There was a widely variable time from transplantation to the appearance of HBV markers in liver or serum, ranging from 6-331 days. Hepatitis D antigen (HDAg) appeared in three grafts very rapidly after transplantation at 4, 8, and 37 days respectively. Graft infection by HBV was accompanied by significant liver injury in six allografts in five recipients. In particular, there was a striking morphological appearance in five infected livers in which the hepatocytes became progressively enlarged and distorted as they accumulated huge amounts of hepatitis B surface and core antigens (HBsAg, HBcAg). These features were accompanied by pericellular fibrosis and cholestasis but little associated inflammation. This syndrome carried a poor prognosis. A gradual progression to cirrhosis occurred in one additional liver. Finally, recurrent HBV infection was a principal or a contributing factor in all deaths. The presence of HBcAg and inflammation in he native liver increased the risk of HBV induced tissue damaged in the graft whereas HDV infection in the host liver seemed to reduce the risk of significant HBV induced tissue damage in the allograft. These data suggest that post transplant HBV infection is accompanied by a variety of changes in the liver allograft, some of which are unique to the transplanted liver and may result in impaired allograft function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446866      PMCID: PMC1379610          DOI: 10.1136/gut.33.10.1390

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  Primary hepatocellular carcinoma after orthotopic liver transplantation for chronic hepatitis B infection.

Authors:  V A Luketic; M L Shiffman; J B McCall; M P Posner; A S Mills; R L Carithers
Journal:  Ann Intern Med       Date:  1991-02-01       Impact factor: 25.391

2.  Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Application for clinical diagnosis.

Authors:  S Kaneko; R H Miller; A M Di Bisceglie; S M Feinstone; J H Hoofnagle; R H Purcell
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

3.  Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide.

Authors:  D H Persing; H E Varmus; D Ganem
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations.

Authors:  A J Demetris; S Todo; D H Van Thiel; J J Fung; Y Iwaki; G Sysyn; W Ming; J Trager; T E Starzl
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

6.  Immunoperoxidase staining of the HBV-associated delta antigen in paraffinated liver specimens.

Authors:  S Recchia; R Rizzi; F Acquaviva; M Rizzetto; V Tison; F Bonino; G Verme
Journal:  Pathologica       Date:  1981 Sep-Oct

7.  Orthotopic liver transplantation totally corrects factor IX deficiency in hemophilia B.

Authors:  R M Merion; R E Delius; D A Campbell; J G Turcotte
Journal:  Surgery       Date:  1988-11       Impact factor: 3.982

8.  Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model.

Authors:  C Féray; A L Zignego; D Samuel; A Bismuth; M Reynes; P Tiollais; H Bismuth; C Brechot
Journal:  Transplantation       Date:  1990-06       Impact factor: 4.939

9.  Liver transplantation in hepatitis delta virus disease.

Authors:  M Rizzetto; S Macagno; E Chiaberge; G Verme; F Negro; G Marinucci; C di Giacomo; D Alfani; R Cortesini; F Milazzo
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

10.  Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders.

Authors:  J R Wands; C M Chura; F J Roll; W C Maddrey
Journal:  Gastroenterology       Date:  1975-01       Impact factor: 22.682

View more
  9 in total

1.  Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients.

Authors:  S Stoll-Becker; R Repp; D Glebe; S Schaefer; J Kreuder; M Kann; F Lampert; W H Gerlich
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 2.  Pre- and Post-Transplant Antiviral Therapy (HBV, HCV).

Authors:  Martin-Walter Welker; Stefan Zeuzem
Journal:  Visc Med       Date:  2016-04-08

3.  Fibrosing cholestatic hepatitis in a kidney transplant recipient with hepatitis C virus.

Authors:  Takahiro Shinzato; Taro Kubo; Toshihiro Shimizu; Koji Nanmoku; Takashi Yagisawa
Journal:  CEN Case Rep       Date:  2019-01-02

Review 4.  Application of nucleoside analogues to liver transplant recipients with hepatitis B.

Authors:  Zhuo-Lun Song; Yu-Jun Cui; Wei-Ping Zheng; Da-Hong Teng; Hong Zheng
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

5.  Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis.

Authors:  Shu-Yuan Xiao; Liang Lu; Hanlin L Wang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

6.  Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation.

Authors:  Vignan Manne; Ruby M Allen; Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-03

7.  Initiation of liver transplantation in bangladesh: report on the first two successful cases.

Authors:  Mohammad Ali; Subash Gupta; S M A Zafar; Mamunur Rashid; Muhd Mustaque Husain; Hashim Rabbi; A H M Tanvir Ahmed; K M Akhtar; Hasina Alam
Journal:  J Health Popul Nutr       Date:  2014-12       Impact factor: 2.000

Review 8.  Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management.

Authors:  Ranjit Chauhan; Shilpa Lingala; Chiranjeevi Gadiparthi; Nivedita Lahiri; Smruti R Mohanty; Jian Wu; Tomasz I Michalak; Sanjaya K Satapathy
Journal:  World J Hepatol       Date:  2018-03-27

9.  Hepatitis B recurrence after liver transplantation: a single center experiences and review the literature.

Authors:  Seyed Mohsen Dehghani; Seyed Ali Reza Taghavi; Bita Geramizadeh; Saman Nikeghbalian; Nima Derakhshan; Abdorrasoul Malekpour; Seyed Ali Malek-Hosseini
Journal:  Hepat Mon       Date:  2013-01-01       Impact factor: 0.660

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.